CureVac NV To Discuss the Shift Focus of COVID-19 Vaccine Development to Second-Generation mRNA Technology Call Transcript

Oct 12, 2021 / 01:00PM GMT
Sarah Fakih - CureVac N.V. - VP Corporate Communications & IR

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President, Investor Relations and Corporate Communications at CureVac.

Please let me introduce today's speaker. On the call with me from CureVac are Franz-Werner Haas, the Chief Executive Officer of CureVac; Pierre Kemula, our Chief Financial Officer; and Klaus Edvardsen, Chief Development Officer of CureVac. From GSK, we are joined today by Rino Rappuoli, Head of Vaccines R&D.

Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our website.

Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's view as of today, Tuesday, October 12, 2021. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot